NCT03029351View on ClinicalTrials.gov

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

PHASE4TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 10, 2017

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Type2 DiabetesKidney Diseases
Interventions
DRUG

Exenatide Extended Release for Inj Susp 2 MG

Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria

DRUG

Placebo

placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria

Trial Locations (1)

14221

Diabetes Endocrinology Research Center of WNY, Williamsville

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University at Buffalo

OTHER